Browse the evidence

GLP-1 receptor agonists (semaglutide) and dual agonists (tirzepatide) are clinically effective for glycemic control and significant weight loss, with tirzepatide demonstrating superior magnitude of weight loss compared to semaglutide in head-to-head trials.

GLP-1 and dual agonists are highly effective for weight loss and blood sugar control. Tirzepatide generally produces greater weight loss than semaglutide. However, high costs and insurance restrictions (often requiring prior failure of other drugs like metformin) limit access. Discuss cardiovascular benefits if you have existing heart disease.

Tirzepatide treatment (10-15 mg once weekly) significantly improves waist-to-height ratio (WHtR) categories compared to placebo, with 54.7% of participants improving their WHtR category at 72 weeks versus 9.6% on placebo.

If you have obesity or overweight with related health complications, treatment with tirzepatide (10-15 mg weekly) combined with lifestyle changes significantly improves your waist-to-height ratio, a key marker for cardiometabolic risk, far more effectively than placebo. This suggests a substantial reduction in central adiposity.

Tirzepatide produced a mean weight loss of −7.14 kg in individuals without diabetes and −5.87 kg in individuals with type 2 diabetes (T2D).

Tirzepatide may be an effective option for weight management in both diabetic and non-diabetic obese adults.

Supplementation with Vicia faba protein hydrolysate (VFH) at a low dose of 2.4g/day significantly enhances leg strength and muscular endurance beyond resistance training alone in healthy, untrained adults.

Take 2.4g of Vicia faba protein hydrolysate daily with your first meal while doing resistance training 3 times a week. This specific supplement has been shown to improve leg strength and endurance more than training alone, even without increasing your total protein intake.

Vicia faba protein hydrolysate (VFH) supplementation significantly increases Bone Mineral Content (BMC) compared to placebo when combined with resistance training.

If you are concerned about bone health, this specific supplement taken with resistance training may help increase bone mineral content, showing a 0.7% increase over 8 weeks.

Structured physical activity of at least 150 minutes per week significantly reduces HbA1c levels in individuals with Type 2 diabetes.

Aim for at least 150 minutes of moderate aerobic exercise (like brisk walking or cycling) every week. If time is tight, try High-Intensity Interval Training (HIIT) for shorter, effective sessions. Consistency matters more than intensity for long-term glucose control.

GLP-1 receptor agonists (e.g., Semaglutide, Liraglutide) and SGLT-2 inhibitors improve glycemic control, body weight, and cardiovascular risk factors in obese patients with type 2 diabetes.

If lifestyle changes alone are insufficient, medications like GLP-1 agonists (e.g., Semaglutide) or SGLT-2 inhibitors can help manage blood sugar and support weight loss. These are prescribed when lifestyle interventions fail to meet targets.

Focusing on carbohydrate quality (high fiber, low glycemic load) is more effective for obesity management than restricting carbohydrate quantity (low-carb diets).

Prioritize the type of carbohydrates you eat over the amount. Choose whole grains, legumes, and fruits that are high in fiber and have a low glycemic impact. This approach supports better metabolic health and weight management compared to simply cutting out carbs.

Moderate-to-vigorous physical activity (MVPA) performed during morning hours (06:00–12:00) significantly reduces the risk of developing diabetic retinopathy (DR) and slows retinal thinning, whereas late-night physical activity increases DR risk.

If you have diabetes or are at risk, aim for at least 150 minutes of moderate-to-vigorous exercise per week. Crucially, try to schedule these workouts in the morning (between 6 AM and 12 PM). This timing appears to offer the strongest protection against diabetic eye disease. Avoid exercising late at night (midnight to 6 AM), as this may increase your risk.

Tirzepatide (10 mg and 15 mg) achieves statistically equivalent total body weight loss to sleeve gastrectomy (SG), with both interventions demonstrating superior efficacy compared to other pharmacotherapies.

If you are an adult with obesity, high-dose Tirzepatide (10-15 mg weekly) can help you lose approximately 21% of your body weight, which is statistically the same amount of weight loss achieved by sleeve gastrectomy surgery. This makes it a highly effective non-surgical option, though it requires weekly injections and lifestyle modifications.

Tirzepatide (5, 10, and 15 mg once weekly) produces significantly greater weight loss than both placebo and GLP-1 receptor agonists (semaglutide, dulaglutide) in adults with overweight or obesity.

If you have overweight or obesity, tirzepatide (administered once weekly) is a highly effective pharmacological option for weight loss, outperforming both placebo and existing GLP-1 medications like semaglutide. Expect significant weight reduction (up to ~12.5 kg with the highest dose) and a higher likelihood of achieving major weight loss milestones (5%, 10%, 15%). Be prepared for potential gastrointestinal side effects (nausea, diarrhea), which are common but often manageable and comparable to other drugs in this class. Consult a healthcare provider to determine if you are a candidate based on your BMI and health status.

Once-weekly tirzepatide (5, 10, or 15 mg) combined with lifestyle intervention produces statistically significant and clinically meaningful body weight reductions (up to -22.4%) and improvements in cardiometabolic risk factors in Japanese adults with obesity or overweight.

For Japanese adults with obesity or overweight, adding once-weekly tirzepatide to a standard lifestyle program (calorie deficit and exercise) leads to substantial weight loss (up to ~22%) and improves heart health markers like blood pressure and cholesterol. While injections are required, side effects like nausea are common but usually mild and temporary. This treatment is specifically approved and effective for this demographic, who may face higher health risks at lower BMIs compared to other ethnicities.

A 12-week low-glycemic index (LGI) diet produces significantly greater reductions in waist circumference, LDL cholesterol, non-HDL cholesterol, and leptin, along with greater increases in GLP-1, compared to a matched low-energy diet (LED) in women with excess body weight, without causing a decline in resting metabolic rate.

To improve your metabolic health and reduce belly fat, switch to a low-glycemic index diet for 12 weeks. Focus on eating foods with a GI of 55 or less freely, limit moderate-GI foods to two servings a day, and avoid high-GI foods. You do not need to strictly count calories; eat until you are satisfied. This approach has been shown to lower bad cholesterol, reduce belly fat more effectively than standard dieting, and improve hormonal markers like GLP-1 without slowing down your metabolism.

The Mediterranean diet reduces visceral adiposity and insulin resistance, key drivers of metabolic syndrome.

Focus on reducing visceral fat by following a Mediterranean diet rich in fiber and healthy fats. This helps improve insulin sensitivity and reduces the risk of metabolic syndrome, even if total body weight changes are gradual.

Tirzepatide produces significantly greater weight loss and glycemic improvement than semaglutide when used at comparable maintenance dosages and adherence levels.

If you are choosing between Semaglutide and Tirzepatide, Tirzepatide tends to produce greater weight loss (approx. 12% vs 8% average in this study). However, this benefit is only realized if you stay on the medication. If you struggle with side effects or cost, switching drugs may not solve the problem if you end up discontinuing.

Prevention or delay of type 2 diabetes through intensive lifestyle intervention or metformin is associated with a lower prevalence of microvascular complications (retinopathy, nephropathy, neuropathy) compared to those who progress to diabetes.

Avoiding or delaying the onset of type 2 diabetes significantly reduces your risk of developing serious microvascular complications like eye, kidney, and nerve damage. This benefit is observed even if you don't take medication, as long as you prevent or delay diabetes.

Low-carbohydrate diets significantly improve glycemic control (HbA1c and FPG) and lipid profiles (reduced triglycerides, increased HDL) in overweight or obese patients with Type 2 Diabetes Mellitus compared to control diets.

If you have Type 2 Diabetes and are overweight, reducing your carbohydrate intake to under 26% of your daily calories can significantly lower your HbA1c and fasting blood sugar. It also improves your blood fat profile by lowering triglycerides and raising good HDL cholesterol, without negatively affecting your LDL. You should work with your doctor to adjust diabetes medications (like insulin) to avoid low blood sugar as you start this diet.

Subcutaneous tirzepatide is the most cost-effective anti-obesity medication for adults without diabetes over a 68-week period, demonstrating superior incremental cost-effectiveness compared to oral semaglutide, subcutaneous semaglutide, and subcutaneous liraglutide.

For adults without diabetes seeking weight loss, subcutaneous tirzepatide offers the best value for money among current GLP-1 based therapies over a 68-week period. It is more cost-effective than oral semaglutide, subcutaneous semaglutide, and subcutaneous liraglutide. While oral semaglutide is a good alternative for those who dislike injections, tirzepatide provides superior cost-effectiveness. Patients should discuss these options with their healthcare provider, considering factors like injection preference, insurance coverage, and potential side effects.

GLP-1 receptor agonists (GLP-1 RAs) are effective for preoperative weight loss in orthopaedic surgery patients with obesity and type-2 diabetes, reducing surgical risk without increasing postoperative complications.

If you are having orthopaedic surgery and take GLP-1s (like Ozempic or Wegovy), tell your surgeon and anesthesiologist. You likely need to stop taking them a week before (for weekly doses) or on the day of (for daily doses) to prevent stomach issues during anesthesia. This helps ensure your surgery goes smoothly and reduces infection risk.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, provides superior glycemic control and weight loss compared to GLP-1 receptor agonists alone, while offering cardioprotective benefits through lipid lowering and anti-inflammatory mechanisms.

Tirzepatide is a once-weekly injection that activates two gut hormones (GIP and GLP-1) to lower blood sugar, reduce appetite, and protect the heart. It is more effective than older GLP-1 drugs for weight loss and blood sugar control. Start with a low dose to minimize stomach upset, and work with your doctor to find the right dose for you.

GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) produce clinically significant weight loss (approx. 10-22%) but are associated with high rates of gastrointestinal adverse events.

GLP-1 medications like semaglutide and tirzepatide are highly effective for significant weight loss (10-22%+), but they come with notable gastrointestinal side effects. They are most effective when combined with lifestyle changes and psychological support, rather than used in isolation.

Consuming 20–40g of whey protein immediately after resistance exercise significantly increases myofibrillar fractional synthetic rate (FSR) and activates the AKT/mTOR signaling pathway (AKT, mTOR, 4E-BP1, p70S6K, rpS6) in healthy adults, thereby extending the post-exercise anabolic window.

For healthy adults engaging in resistance training, consuming 20-40g of whey protein around your workout (either immediately after or up to 45 minutes before) significantly boosts muscle protein synthesis compared to placebo. This strategy activates the AKT/mTOR pathway, which drives muscle repair and growth. You do not need to consume excessive amounts (>40g) to see benefits, and pre-workout consumption may even offer a slight edge in FSR magnitude for some protocols.

Omega-3 fatty acid supplementation (≥1 g/day) supports muscle quality, cardiovascular health, and reduces inflammation during GLP-1RA treatment.

Take at least 1 gram of Omega-3 fatty acids daily. This helps protect your heart, reduces inflammation, and may support muscle quality while you lose weight.

In patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, achieving MASH resolution and fibrosis improvement is significantly associated with greater reductions in body weight, improved glycemic control (HbA1c), and normalization of liver fat.

If you have MASH with fibrosis, achieving significant weight loss, better blood sugar control, and normalizing liver fat are key steps toward resolving the disease. Tirzepatide, taken once weekly and titrated up from 2.5mg to 5-15mg over several months, has been shown to facilitate these metabolic changes, which in turn drive histological improvement in the liver.